Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
2012
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2011
  • All years
Non Regulatory
December 6, 2012

Interim report for the period May – October 2012

Non Regulatory
December 3, 2012

Nexttobe AB and Alceco International S.A. increase their ownership in Oasmia

Regulatory
November 30, 2012

Publication of change in the total number of shares and votes in Oasmia

Non Regulatory
November 15, 2012

Final result of Oasmia’s rights issue

Non Regulatory
November 12, 2012

Preliminary result of Oasmia’s rights issue

Non Regulatory
October 25, 2012

Prospectus regarding Oasmia Pharmaceutical’s rights issue is now available

Regulatory
October 18, 2012

Oasmia Pharmaceutical AB announces a fully committed and underwritten rights issue of SEK 123 million

Non Regulatory
September 24, 2012

Communiqué from Annual General Meeting 2012

Non Regulatory
September 10, 2012

Oasmia Pharmaceutical AB has signed a Memorandum of Understanding regarding business collaboration in Russia

Non Regulatory
September 7, 2012

Clarification regarding previous statements by the CFO

Regulatory
September 6, 2012

Interim report for the period May – July 2012

Non Regulatory
August 24, 2012

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

Non Regulatory
August 23, 2012

The Oasmia Pharmaceutiacal Annual Report is now published

Non Regulatory
July 4, 2012

FDA grants Oasmia MUMS designation for Doxophos® Vet

Non Regulatory
June 14, 2012

Year-end report for the fiscal year May 2011- April 2012

Non Regulatory
March 9, 2012

Paccal Vet® update on the European Regulatory process

Non Regulatory
March 8, 2012

Interim report May 1, 2011 – January 31, 2012

Non Regulatory
January 16, 2012

FDA grants Paccal® Vet Minor Use designation for mammary tumors

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com